181 related articles for article (PubMed ID: 27698228)
1. Transcriptional Regulation of CYP2D6 Expression.
Pan X; Ning M; Jeong H
Drug Metab Dispos; 2017 Jan; 45(1):42-48. PubMed ID: 27698228
[TBL] [Abstract][Full Text] [Related]
2. Farnesoid X Receptor Agonist Represses Cytochrome P450 2D6 Expression by Upregulating Small Heterodimer Partner.
Pan X; Lee YK; Jeong H
Drug Metab Dispos; 2015 Jul; 43(7):1002-7. PubMed ID: 25926433
[TBL] [Abstract][Full Text] [Related]
3. Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.
He ZX; Chen XW; Zhou ZW; Zhou SF
Drug Metab Rev; 2015; 47(4):470-519. PubMed ID: 26574146
[TBL] [Abstract][Full Text] [Related]
4. Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice.
Koh KH; Pan X; Shen HW; Arnold SL; Yu AM; Gonzalez FJ; Isoherranen N; Jeong H
J Biol Chem; 2014 Feb; 289(6):3105-13. PubMed ID: 24318876
[TBL] [Abstract][Full Text] [Related]
5. Cholic Acid Feeding Leads to Increased CYP2D6 Expression in CYP2D6-Humanized Mice.
Pan X; Kent R; Won KJ; Jeong H
Drug Metab Dispos; 2017 Apr; 45(4):346-352. PubMed ID: 28153841
[TBL] [Abstract][Full Text] [Related]
6. Estrogen-Induced Cholestasis Leads to Repressed CYP2D6 Expression in CYP2D6-Humanized Mice.
Pan X; Jeong H
Mol Pharmacol; 2015 Jul; 88(1):106-12. PubMed ID: 25943116
[TBL] [Abstract][Full Text] [Related]
7. Effects of Fenofibrate on the Expression of Small Heterodimer Partner (SHP) and Cytochrome P450 (CYP) 2D6.
Kent R; Jeong H
Drug Metab Lett; 2017 Nov; 11(1):68-72. PubMed ID: 28403802
[TBL] [Abstract][Full Text] [Related]
8. Krüppel-like factor 9 promotes hepatic cytochrome P450 2D6 expression during pregnancy in CYP2D6-humanized mice.
Koh KH; Pan X; Zhang W; McLachlan A; Urrutia R; Jeong H
Mol Pharmacol; 2014 Dec; 86(6):727-35. PubMed ID: 25217496
[TBL] [Abstract][Full Text] [Related]
9. Induction of CYP2D6 in pregnancy.
Wadelius M; Darj E; Frenne G; Rane A
Clin Pharmacol Ther; 1997 Oct; 62(4):400-7. PubMed ID: 9357391
[TBL] [Abstract][Full Text] [Related]
10. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.
Thuerauf N; Lunkenheimer J
Eur Arch Psychiatry Clin Neurosci; 2006 Aug; 256(5):287-93. PubMed ID: 16783493
[TBL] [Abstract][Full Text] [Related]
11. Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6.
Haertter S
Drug Metabol Drug Interact; 2013; 28(4):209-16. PubMed ID: 24088607
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte nuclear factor (HNF) 4α transactivation of cytochrome P450 (Cyp) 2d40 promoter is enhanced during pregnancy in mice.
Ning M; Koh KH; Pan X; Jeong H
Biochem Pharmacol; 2015 Mar; 94(1):46-52. PubMed ID: 25598084
[TBL] [Abstract][Full Text] [Related]
13. Determinants of Cytochrome P450 2D6 mRNA Levels in Healthy Human Liver Tissue.
Ning M; Duarte JD; Stevison F; Isoherranen N; Rubin LH; Jeong H
Clin Transl Sci; 2019 Jul; 12(4):416-423. PubMed ID: 30821899
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 Protein Level Is the Major Contributor to Interindividual Variability in CYP2D6-Mediated Drug Metabolism in Healthy Human Liver Tissue.
Ning M; Duarte JD; Rubin LH; Jeong H
Clin Pharmacol Ther; 2018 Nov; 104(5):974-982. PubMed ID: 29349771
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D receptor activation down-regulates the small heterodimer partner and increases CYP7A1 to lower cholesterol.
Chow EC; Magomedova L; Quach HP; Patel R; Durk MR; Fan J; Maeng HJ; Irondi K; Anakk S; Moore DD; Cummins CL; Pang KS
Gastroenterology; 2014 Apr; 146(4):1048-59. PubMed ID: 24365583
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6 mRNA expression in circulating peripheral blood mononuclear cells correlates with in vivo debrisoquine hydroxylase activity in extensive metabolizers.
Carcillo JA; Parise RA; Adedoyin A; Frye R; Branch RA; Romkes M
Res Commun Mol Pathol Pharmacol; 1996 Feb; 91(2):149-159. PubMed ID: 8832907
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM; Raimundo S; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
[TBL] [Abstract][Full Text] [Related]
19. The importance of heterogeneous nuclear ribonucleoprotein K on cytochrome P450 2D2 gene regulation: its binding is reduced in Dark Agouti rats.
Sakai N; Sakamoto KQ; Fujita S; Ishizuka M
Drug Metab Dispos; 2009 Aug; 37(8):1703-10. PubMed ID: 19420131
[TBL] [Abstract][Full Text] [Related]
20. Linkage disequilibrium mapping identifies a 390 kb region associated with CYP2D6 poor drug metabolising activity.
Hosking LK; Boyd PR; Xu CF; Nissum M; Cantone K; Purvis IJ; Khakhar R; Barnes MR; Liberwirth U; Hagen-Mann K; Ehm MG; Riley JH
Pharmacogenomics J; 2002; 2(3):165-75. PubMed ID: 12082588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
